These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 28539177)

  • 1. Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning.
    Pinkerton JV; Bushmakin AG; Komm BS; Abraham L
    Maturitas; 2017 Jun; 100():57-63. PubMed ID: 28539177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menopause-specific quality of life across varying menopausal populations with conjugated estrogens/bazedoxifene.
    Abraham L; Pinkerton JV; Messig M; Ryan KA; Komm BS; Mirkin S
    Maturitas; 2014 Jul; 78(3):212-8. PubMed ID: 24837362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
    Alvisi S; Lami A; Baldassarre M; Lenzi J; Mancini I; Seracchioli R; Meriggiola MC
    J Sex Med; 2022 May; 19(5):761-770. PubMed ID: 35370104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.
    Kingsberg SA; Wysocki S; Magnus L; Krychman ML
    J Sex Med; 2013 Jul; 10(7):1790-9. PubMed ID: 23679050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a new vaginal gel for the treatment of symptoms associated with vulvovaginal atrophy in postmenopausal women: A double-blind randomized placebo-controlled study.
    De Seta F; Caruso S; Di Lorenzo G; Romano F; Mirandola M; Nappi RE
    Maturitas; 2021 May; 147():34-40. PubMed ID: 33832645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.
    Pinkerton JV; Bushmakin AG; Abraham L; Cappelleri JC; Komm BS
    Menopause; 2016 Oct; 23(10):1092-101. PubMed ID: 27404026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.
    Nappi RE; Palacios S; Panay N; Particco M; Krychman ML
    Climacteric; 2016 Apr; 19(2):188-97. PubMed ID: 26581580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy.
    Bruyniks N; Nappi RE; Castelo-Branco C; de Villiers TJ; Simon J
    Climacteric; 2016; 19(1):60-5. PubMed ID: 26669628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device.
    Vicariotto F; Raichi M
    Minerva Ginecol; 2016 Jun; 68(3):225-36. PubMed ID: 27206062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV; Stanczyk FZ
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety.
    Vicariotto F; DE Seta F; Faoro V; Raichi M
    Minerva Ginecol; 2017 Aug; 69(4):342-349. PubMed ID: 28608667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women.
    Panay N; Palacios S; Bruyniks N; Particco M; Nappi RE;
    Maturitas; 2019 Jun; 124():55-61. PubMed ID: 31097180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Vulvovaginal Atrophy Symptoms and Quality of Life Among Postmenopausal Women in the United States and Western Europe.
    DiBonaventura M; Luo X; Moffatt M; Bushmakin AG; Kumar M; Bobula J
    J Womens Health (Larchmt); 2015 Sep; 24(9):713-22. PubMed ID: 26199981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial.
    Archer DF; Goldstein SR; Simon JA; Waldbaum AS; Sussman SA; Altomare C; Zhu J; Yoshida Y; Schaffer S; Soulban G
    Menopause; 2019 Jan; 26(6):611-621. PubMed ID: 30694917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy.
    Wang J; Wang L
    Pharmacol Res; 2021 Apr; 166():105509. PubMed ID: 33610719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.